Nucleic acid detection above the base air vent.

how to make use of the opportunity of this nucleic acid reagent heat, to promote their own strength, is the ultimate issue to considerrecently, after the outbreak of new areas, nucleic acid testing has once again become a hot topic in BeijingIn the face of "should be inspected, willing to inspect" advocacy and a large demand base, Beijing's nucleic acid detection capacity once appeared supply and demand contradictions, including testing appointment tension and nucleic acid testing prices are not the samein order to solve the above-mentioned problems, on June 19, the State Health Insurance Administration issued a "notice on cooperation to further improve the detection capacity of the new coronavirus notice." The "Notice" clearly, all localities should take into account the new crown pneumonia prevention and control work needs, the region's medical insurance fund to pay capacity and other factors, according to the procedures for the new crown virus nucleic acid, antibody testing projects and related supplies into the provincial medical insurance diagnosis and treatment project directory, and simultaneously determine the payment conditionsin addition to being included in health insurance, nucleic acid testing and drugs, equipment, is currently facing a new round of centralized procurement policyFor example, on June 15, the Beijing Municipal Health Insurance Bureau announced the results of the Beijing-Tianjin-Yuan New Crown Virus-related Testing Reagents joint lying online on the Beijing Municipal Pharmaceutical Centralized Procurement Information Networkresults show that the number of selected enterprises for the domestic centralized procurement of new crown reagents since the largest, many enterprises began to give up to maintain the previous price system, into the low-cost killing battlefieldAlthough the purchase price of the kit has come down, but for the production of nucleic acid reagents, the future is just beginningHow to use the opportunity of this nucleic acid reagent heat, to promote their own strength, perhaps is the ultimate question they need to considerBeijing East Children's Hospital is a private high-end medical institution, the hospital's chief executive Ma Yuehong told the health community, the hospital is currently signed a long-term cooperation agreement with Epyi Medical, nucleic acid testing, Epyi told the health community, Epyi and medical institutions, the cooperative model is based on its testing, pathology, high flux direction 13 laboratories of the rich testing platform and projects, for medical institutions to provide the necessary testing programs to supplement, so as to support the diagnosis and treatment of various types of patientsin fact, for testing agencies, in addition to cooperation with medical institutions, they also bear the task of government-directed nucleic acid testing, which also led to a large sample size, the agency staff shortageis understood that at present, most of Beijing's detection agencies of individuals, groups and other nucleic acid testing business daily limit number of about 500 peopleStaff at the Benny Medical Testing Laboratory, another third-party medical testing agency in Beijing, told the health community that if the current appointment is made, the time of mid-July can only be booked, and the previous dates have been fullandd emptyIn addition to the delay in the waiting time for an appointment, the time for the inspectors to get the report is also getting longer"Last month (May) Beijing's nucleic acid testing was basically available within 24 hours, but now it takes four to five days, " the staff said"It's worth noting that most test reports are currently only seven days old, which means that in Beijing, even if you get the test report, it's only two to three days Therefore, multiple tests are inevitable if necessary large-scale testing in Beijing, to some enterprises to bring testing pressure, but also brought business growth opportunities According to Epyi, the agency's laboratory tests have skyrocketed since the outbreak, leaving employees who are just about to return to normal rest to be busy or overstretched Under the condition of strong control, the daily sample volume has also been increased from the previous 8000 copies/day of task detection to more than 20,000 copies/day Correspondingly, daily business volume increased by nearly 2.5 times in addition to Epyi, Beijing Benny Medical Testing Laboratory also told the health community, "before the day to do the test more than a thousand people, now is a day tens of thousands of people tested." "
testing is behind the surge in revenue According to the previous Beijing nucleic acid detection of the highest price of 180 yuan per person, ten times the increase means a daily increase of nearly 1.8 million yuan in income in addition to the inspection institutions, due to the downstream third-party medical testing institutions of the demand for nucleic acid reagents soared, in the upper reaches of the industrial chain enterprises have also tasted the sweetness by incomplete statistics of the health sector, the current domestic new crown virus testing reagents manufacturers involved in a total of about 12 A-share listed companies such as Da'an Gene, WantaI Bio, Huada Gene In the secondary market performance, the in vitro diagnostic sector since January 2020, as of the close of June 24, the sector has risen 69.55 percent among the , Huada Gene rose 110.92 percent over the same period, with a total market value of 57.97 billion yuan, DaanGene rose 162.80 percent in the same period, the stock price reached a new high for the year, And Wantai Bio launched the capital market earlier this year, the listing of 18 ups and downs, the share price rose from 8.75 yuan to a maximum of 170 yuan, capital enthusiasm can be seen according to the data, in the first quarter of 2020, The Company, Daan Gene, Oriental Bio, Wanfu Bio, Wantai Bio, Heating Biology, Huada Gene, Lizhu Group and other stocks achieved a year-on-year increase in net profit attributable to Among them, The net profit attributable to Shishi Bio in the first quarter of this year was about 104 million yuan, up 670.91 percent year-on-year, and Wanfu Bio achieved a net profit of about 978.458 million yuan in the first quarter of this year, up 34.82 percent year-on-year As for the reasons for the company's performance growth, Wanfu Bio mentioned that the company's outbreak-related testing productsales revenue continued to grow rapidly the first quarter of the performance of the above-mentioned nucleic acid testing stocks also worth looking forward to The company's first half of this year's results were disclosed by The Company, in which Sussi Bio said in a statement that the first half of this year's net profit will increase significantly compared with the same period last year due to a surge in sales of new crown testing reagents in the first quarter of 2020, and DaanGene said that the first half of this year's net profit will be about 303 million yuan - 450 million yuan, an increase in the year-on-year range of 400% - 643.64 percent for the future development of the entire industry, Huaxi Securities in the research report predicted that the new crown pneumonia detection to promote the concept of nucleic acid detection and the establishment of hardware and software conditions, will greatly promote the establishment of nucleic acid testing laboratory This outbreak, will greatly promote the development of the nucleic acid testing industry, the future of the domestic with over 10,000 nucleic acid testing capacity of the institutions, nucleic acid testing operations and personnel barriers no longer exist Nucleic acid testing enterprises will greatly benefit from the nucleic acid infrastructure improvement brought about by the development of the nucleic acid testing industry stand on top of the wind, nucleic acid testing is also a lot of controversy, including the accuracy of testing reagents and high prices and other issues The former is mainly the technical problems of each manufacturer itself, which should be solved after the technology matures, while the pricing of nucleic acid testing reagents is the most realistic problem facing the public for example to go to public hospital testing, generally need to spend 50 yuan in the hospital registration, and then spend 180 yuan to do nucleic acid testing Some people can't wait to queue, or even to the private hospital to spend 1600 yuan to do a test in the face of this phenomenon, the Beijing Municipal Health Insurance Bureau on June 28 again announced that the Beijing public hospital nucleic acid testing to reduce the guidance price, from 180 yuan to 120 yuan, medical institutions are not allowed to float In fact, this is just one of the official measures to curb accounting testing price increases After all, for the public, there has been a discussion about the low cost of testing kits, high fees, whether "profiteering" faced with public doubts, nucleic acid testing agencies are full of grievances A nucleic acid medical related person in charge told the health community, nucleic acid testing around the price-setting main and testing costs related And the cost of testing is not only related to the purchase price of reagents, supplies, protective supplies, etc., but also related to the wage level of technical and logistical support personnel, government subsidies, etc are related "We've noticed recent questions about the costs raised by individuals on the Internet, but I would say that if people are willing to go out of the office and really engage with their first-line partners, they'll find that they're willing to pay not because of bonuses or benefits, but with a lot of blood and responsibility." The person in charge said in order to solve the public's doubts about the price, the Beijing Municipal Health Insurance Bureau has also started the centralized procurement of nucleic acid reagents, with the intention of lowering prices from the procurement process June 15, the Beijing Municipal Health Insurance Bureau in Beijing Pharmaceutical Centralized Procurement Information Online to announce the Beijing-Tianjin-Yuan New Crown Virus-related testing reagents joint procurement of the results of the network transaction The results show that the number of selected enterprises for the domestic centralized procurement of new crown reagents since the largest, many enterprises began to give up the maintenance of the previous price system, into the low-cost killing battlefield According to the results of the winning bid published by the Beijing Municipal Health Insurance Bureau, the collection of nucleic acid reagents in Beijing has obviously reduced the relevant prices According to the price list, a total of 24 companies won the bid for the Beijing-Tianjin-Hebei alliance, involving a number of listed companies, including Da'an Gene, Mike Bio, Mingde Bio, Oriental Bio, as well as Fosun Pharma's Shanghai Fosun Long March the lowest price for nucleic acid and antibody testing reagents in this offer is the lowest level in the region where centralized procurement has been carried out Among them, the new crown virus nucleic acid testing reagents have 11 kinds, antibody testing reagents have 19 kinds, nucleic acid testing reagents involved in the company 11, the minimum commitment supply price of Shenzhen United Medicine 12 yuan / person, the new crown antibody testing reagent group involved in the company 14, the lowest commitment supply price of 5.8 yuan / person from all over the collection of winning enterprises list published to the present, the supply situation of enterprises is not tight One of the selected enterprises, Mike biology related person in charge in an interview with the health sector, said that from the beginning of the epidemic, the company in the domestic and foreign markets to supply a total of about 900-10 million, has not been subdivided into specific areas of the supply data can be provided, "because the domestic market changes are relatively large, manufacturers are more." "
in fact, Mike Bio has been in a number of provinces at the lowest price, and this time selected nucleic acid testing, IgM, IgG antibody testing kits, declared daily output of 1 million, 1.5 million and 1.5 million, respectively, the price is 15.98 yuan / person, 6.99 yuan / person, 6.99 yuan / person the need for new crown nucleic acid testing with the outbreak, the outbreak will eventually pass, so the current face of many enterprises an important question is: the future of further stability of the epidemic, how to normalize the performance of nucleic acid testing? "It has become a consensus that the new crown virus has long coexisted with humans, " said Shi Lichen, founder of the Dingchen Medical Management Consulting Center in Beijing, , in an interview with the health community The new outbreak in Beijing has also made more people realize that a small regional outbreak of the new crown outbreak, or a small regional outbreak, may become the norm , Shrichen believes that nucleic acid testing will become "daily" in the future In addition to government screening, into cities, out of town, hospital, more scenes need a test report Therefore, under this "new normal", nucleic acid testing this new industry, will continue to sit in the real outbreak of rare performance growth of the "black horse" role, the future performance will continue to grow Also stressed that the relevant nucleic acid testing agencies are also able to use this performance growth period, to complement their own other short board, so that their revenue capacity is more solid in fact, there are now companies that are starting to prepare for the future Epyi told the health community that the center will continue to maintain the wartime laboratory equipment configuration after the outbreak stabilizes, adjust the staffing according to actual needs to meet the actual needs of the new crown testing, while adjusting the business focus For the nucleic acid detection platform project, the center not only has the current new crown detection, but also for conventional tumor, cardiovascular and other diseases testing projects, a variety of business composition can promote the comprehensive development of institutions, reduce the risk of dependence of a single business at present, the nucleic acid reagent industry is in the wind, many entrants hope to get a piece of this emerging industry But Shi Lichen also reminded: even if the heat is very high, the future as the industry gradually calm down, nucleic acid testing reagents will also be and generic drugs, after experiencing the survival of the fittest, only a small number of powerful enterprises can survive, this is an industry law.